(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States.
The South San Francisco, California-based company is seeking up to $132.6 million by offering 7.8 million shares priced between $15 and $17 each.
The IPO could be one of the several offerings from the biotech sector in the coming weeks as a clutch of pharmaceutical companies look to test investor appetite towards the industry.
Drug developers Aardvark Therapeutics, Aurion Biotech, Sonna Therapeutics, Metsera, and Odyssey Therapeutics are among the IPO hopefuls that have filed their paperwork in recent weeks.
J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities are the underwriters for the offering.
Maze Therapeutics will list on the Nasdaq under the symbol “MAZE”.
(Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Vijay Kishore)
Comments